As a platform company developing drugs against a newly identified class of enzymes, Nitrome Biosciences will have found and characterized this class of enzymes and will have paved a novel inroad into the proprietary development of disease-modifying therapies. They are initially targeting Parkinson’s disease and developing cures for multiple aging-dependent diseases, including other neurodegenerative diseases, Type II diabetes, heart disease, and cancer.

Biotechnology

Nitrome Biosciences

Irene Griswold-Prenner

Sarah Wright

Frank Kayser

Arun Kashyap

Carla Ramos

Gary Probst

Sami Hussain

Kate Markham

The Scientific Team at Nitrome Biosciences is responsible for researching and characterizing the newly identified class of enzymes, developing proprietary drug candidates, and advancing these treatments through the pipeline. Their efforts focus on creating disease-modifying therapies for Parkinson's and other aging-dependent diseases, including neurodegenerative conditions, Type II diabetes, heart disease, and cancer. The team combines expertise in biochemistry, chemistry, biology, and drug discovery to innovate and drive scientific breakthroughs.

Scientific Team

Leadership Team

Scientific Team

About

Team members

Other teams at Nitrome Biosciences

Leadership Team